Cargando…

Deazaneplanocin A Is a Promising Drug to Kill Multiple Myeloma Cells in Their Niche

Tumoral plasma cells has retained stemness features and in particular, a polycomb-silenced gene expression signature. Therefore, epigenetic therapy could be a mean to fight for multiple myeloma (MM), still an incurable pathology. Deazaneplanocin A (DZNep), a S-adenosyl-L-homocysteine hydrolase inhib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gaudichon, Jérémie, Milano, Francesco, Cahu, Julie, DaCosta, Lætitia, Martens, Anton C., Renoir, Jack-Michel, Sola, Brigitte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177844/ https://www.ncbi.nlm.nih.gov/pubmed/25255316 http://dx.doi.org/10.1371/journal.pone.0107009

Ejemplares similares

Estrogenic or antiestrogenic therapies for multiple myeloma?
por: Sola, Brigitte, et al.
Publicado: (2007)

Cyclin D1 sensitizes myeloma cells to endoplasmic reticulum stress-mediated apoptosis by activating the unfolded protein response pathway
por: Bustany, Sophie, et al.
Publicado: (2015)

Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis
por: Bustany, Sophie, et al.
Publicado: (2015)

Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism
por: Sola, Brigitte, et al.
Publicado: (2013)

Cyclin K and cyclin D1b are oncogenic in myeloma cells
por: Marsaud, Véronique, et al.
Publicado: (2010)

Epigenetically Reprogramming of Human Embryonic Stem Cells by 3-Deazaneplanocin A and Sodium Butyrate
por: Azghadi, Soheila, et al.
Publicado: (2011)

3-Deazaneplanocin A (DZNep), an Inhibitor of S-Adenosylmethionine-dependent Methyltransferase, Promotes Erythroid Differentiation
por: Fujiwara, Tohru, et al.
Publicado: (2014)

A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A
por: Zeybel, Müjdat, et al.
Publicado: (2017)

Anti-inflammatory and chondroprotective effects of the S-adenosylhomocysteine hydrolase inhibitor 3-Deazaneplanocin A, in human articular chondrocytes
por: Aury-Landas, Juliette, et al.
Publicado: (2017)

Tumor Necrosis Factor-Alpha and Apoptosis Induction in Melanoma Cells through Histone Modification by 3-Deazaneplanocin A
por: Tanaka, Ryo, et al.
Publicado: (2013)

Evaluation of the impact of S-adenosylmethionine-dependent methyltransferase inhibitor, 3-deazaneplanocin A, on tissue injury and cognitive function in mice
por: Lhuissier, Eva, et al.
Publicado: (2018)

Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML)
por: Jiang, Xia, et al.
Publicado: (2015)

Modelling Duchenne muscular dystrophy in MYOD1-converted urine-derived cells treated with 3-deazaneplanocin A hydrochloride
por: Takizawa, Hotake, et al.
Publicado: (2019)

Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A
por: Sarkar, Subhashis, et al.
Publicado: (2015)

3-Deazaneplanocin A (DZNep), an Inhibitor of the Histone Methyltransferase EZH2, Induces Apoptosis and Reduces Cell Migration in Chondrosarcoma Cells
por: Girard, Nicolas, et al.
Publicado: (2014)

Enhancement of the Antileukemic Action of the Inhibitors of DNA and Histone Methylation: 5-Aza-2′-Deoxycytidine and 3-Deazaneplanocin-A by Vitamin C
por: Momparler, Richard L., et al.
Publicado: (2021)

Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies
por: Storti, Paola, et al.
Publicado: (2020)

Publisher Correction: Modelling Duchenne muscular dystrophy in MYOD1-converted urine-derived cells treated with 3-deazaneplanocin A hydrochloride
por: Takizawa, Hotake, et al.
Publicado: (2020)

Actors on the Scene: Immune Cells in the Myeloma Niche
por: Leone, Patrizia, et al.
Publicado: (2020)

3-deazaneplanocin A protects against cisplatin-induced renal tubular cell apoptosis and acute kidney injury by restoration of E-cadherin expression
por: Ni, Jun, et al.
Publicado: (2019)

Co-Treatment with the Epigenetic Drug, 3-Deazaneplanocin A (DZNep) and Cisplatin after DZNep Priming Enhances the Response to Platinum-Based Therapy in Chondrosarcomas
por: Lhuissier, Eva, et al.
Publicado: (2021)

Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells
por: Cahu, J, et al.
Publicado: (2012)

BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A
por: Puppe, Julian, et al.
Publicado: (2009)

Correction: 3-deazaneplanocin A protects against cisplatin-induced renal tubular cell apoptosis and acute kidney injury by restoration of E-cadherin expression
por: Ni, Jun, et al.
Publicado: (2019)

Inhibition of DNA and Histone Methylation by 5-Aza-2′-Deoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells
por: Momparler, Richard L., et al.
Publicado: (2017)

SASP: roadblock for tissue re-organization
por: Cahu, Julie
Publicado: (2013)

Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche
por: Chillemi, Antonella, et al.
Publicado: (2017)

Natural Killer Cells in the Malignant Niche of Multiple Myeloma
por: Venglar, Ondrej, et al.
Publicado: (2022)

Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?
por: Noll, J E, et al.
Publicado: (2012)

Immunotherapy of Multiple Myeloma: Promise and Challenges
por: Abramson, Hanley N
Publicado: (2021)

Neovascular Niche for Human Myeloma Cells in Immunodeficient Mouse Bone
por: Iriuchishima, Hirono, et al.
Publicado: (2012)

Morphogens and growth factor signalling in the myeloma bone-lining niche
por: Morris, Emma V., et al.
Publicado: (2021)

Bone marrow niche in multiple myeloma and its precursor states
por: Sklavenitis-Pistofidis, Romanos, et al.
Publicado: (2019)

A combination of valproic acid sodium salt, CHIR99021, E-616452, tranylcypromine, and 3-Deazaneplanocin A causes stem cell-like characteristics in cancer cells
por: Sha, Shuang, et al.
Publicado: (2017)

Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma
por: Johnstone, Megan, et al.
Publicado: (2022)

Talquetamab: A promising immunotherapy for multiple myeloma
por: Tariq, Amna, et al.
Publicado: (2023)

Shock and kill within the CNS: A promising HIV eradication approach?
por: Nühn, Marieke M., et al.
Publicado: (2022)

Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche
por: Lawson, Michelle A., et al.
Publicado: (2015)

Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
por: Solimando, Antonio Giovanni, et al.
Publicado: (2022)

PB1966: HEMOPOIETIC NICHE IMPAIRMENT IN TREATED MULTIPLE MYELOMA PATIENTS
por: Semenova, N. Y., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5bduomnrcvnjovik4psdmrqvlc